Castle Biosciences (CSTL) Competitors $16.54 -0.85 (-4.89%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$16.52 -0.02 (-0.09%) As of 07/18/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL vs. VCYT, ADUS, PACS, ARDT, LFST, PGNY, GRAL, NHC, TDOC, and VRDNShould you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Veracyte (VCYT), Addus HomeCare (ADUS), PACS Group (PACS), Ardent Health (ARDT), LifeStance Health Group (LFST), Progyny (PGNY), GRAIL (GRAL), National HealthCare (NHC), Teladoc Health (TDOC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry. Castle Biosciences vs. Its Competitors Veracyte Addus HomeCare PACS Group Ardent Health LifeStance Health Group Progyny GRAIL National HealthCare Teladoc Health Viridian Therapeutics Castle Biosciences (NASDAQ:CSTL) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Does the media prefer CSTL or VCYT? In the previous week, Veracyte had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 9 mentions for Veracyte and 8 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 0.87 beat Veracyte's score of 0.74 indicating that Castle Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CSTL or VCYT? 92.6% of Castle Biosciences shares are owned by institutional investors. 6.5% of Castle Biosciences shares are owned by insiders. Comparatively, 1.4% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is CSTL or VCYT more profitable? Veracyte has a net margin of 7.13% compared to Castle Biosciences' net margin of -1.46%. Veracyte's return on equity of 6.14% beat Castle Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Castle Biosciences-1.46% 3.41% 2.95% Veracyte 7.13%6.14%5.60% Which has more volatility and risk, CSTL or VCYT? Castle Biosciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Do analysts rate CSTL or VCYT? Castle Biosciences presently has a consensus target price of $37.00, indicating a potential upside of 123.70%. Veracyte has a consensus target price of $40.90, indicating a potential upside of 73.97%. Given Castle Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Castle Biosciences is more favorable than Veracyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has preferable earnings and valuation, CSTL or VCYT? Veracyte has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCastle Biosciences$347.08M1.38$18.25M-$0.19-87.05Veracyte$445.76M4.13$24.14M$0.4157.34 SummaryVeracyte beats Castle Biosciences on 10 of the 15 factors compared between the two stocks. Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSTL vs. The Competition Export to ExcelMetricCastle BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$477.54M$2.94B$5.54B$9.43BDividend YieldN/A2.48%4.00%4.03%P/E Ratio-87.0519.8828.2419.77Price / Sales1.38304.49413.6690.13Price / Cash16.8141.8435.8558.18Price / Book1.027.678.115.65Net Income$18.25M-$55.28M$3.25B$257.97M7 Day Performance-15.87%4.87%1.64%3.75%1 Month Performance-12.53%11.73%7.28%11.53%1 Year Performance-16.97%3.72%33.14%19.22% Castle Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSTLCastle Biosciences2.4484 of 5 stars$16.54-4.9%$37.00+123.7%-12.7%$477.54M$347.08M-87.05540News CoveragePositive NewsVCYTVeracyte3.7689 of 5 stars$26.34-4.3%$40.90+55.3%-1.8%$2.15B$445.76M64.25790News CoverageADUSAddus HomeCare4.974 of 5 stars$110.62-1.1%$142.57+28.9%-10.2%$2.06B$1.15B24.9749,703Positive NewsAnalyst ForecastPACSPACS Group2.872 of 5 stars$12.51-4.8%$34.29+174.1%-63.7%$2.00B$3.11B0.0032,433News CoverageARDTArdent Health3.3958 of 5 stars$13.34-0.4%$20.67+54.9%N/A$1.92B$5.97B8.1824,900News CoverageAnalyst DowngradeLFSTLifeStance Health Group3.0547 of 5 stars$4.68-2.3%$8.50+81.6%-23.3%$1.86B$1.25B-46.8010,218PGNYProgyny1.7908 of 5 stars$21.450.0%$23.45+9.3%-21.5%$1.84B$1.17B37.63310Analyst ForecastGRALGRAIL0.681 of 5 stars$44.85-4.0%$31.50-29.8%+108.0%$1.68B$125.60M-0.741,360Insider TradeNHCNational HealthCareN/A$104.23-3.9%N/A-22.4%$1.61B$1.37B13.0612,400TDOCTeladoc Health2.7351 of 5 stars$8.06-2.8%$9.60+19.1%-13.2%$1.45B$2.57B-1.365,500VRDNViridian Therapeutics3.0243 of 5 stars$15.89+1.4%$37.56+136.3%+14.2%$1.28B$300K-4.1350 Related Companies and Tools Related Companies Veracyte Alternatives Addus HomeCare Alternatives PACS Group Alternatives Ardent Health Alternatives LifeStance Health Group Alternatives Progyny Alternatives GRAIL Alternatives National HealthCare Alternatives Teladoc Health Alternatives Viridian Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSTL) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
